ICTC’s 2022-2030 strategic plan spans the critical period running to the end of 2030, the year by which we are striving to achieve the elimination of trachoma as a public health problem. This strategic plan is in alignment with the NTD road map, Ending the neglect to attain the Sustainable Develop...ment Goals: a road map for neglected tropical diseases 2021−2030.
more
Plan stratégique 2022-2030 de l’ICTC
The second edition of the Women and Trachoma: Achieving Gender Equity in the Implementation of SAFE manual provides an updated resource for realistically increasing, improving, and supporting gender representation within trachoma elimination efforts at all levels. From the trachoma workforce to the ...patients, from trichiasis surgeons to schoolteachers, and from national to international managers and coordinators, the manual breaks down the various levels of trachoma elimination programming to highlight the areas where women and girls can have a greater impact in elimination effort
more
Assurer l’égalité des genres dans l’application de la stratégie CHANCE
Esta publicación presenta la Agenda para las Américas sobre salud, medioambiente y cambio climático 2021-2030. Esta agenda es un llamamiento al sector de la salud para que lidere la labor a fin de abordar los determinantes ambientales de la salud en la Región de las Américas. La Organización P...anamericana de la Salud (OPS) colaborará con sus Estados Miembros para alcanzar el propósito y el objetivo de esta agenda de promover el bienestar de todos a todas las edades, utilizando un enfoque sostenible y equitativo en el que se otorgue prioridad a la reducción de las inequidades en la salud. La agenda se ha elaborado bajo la égida de la Estrategia mundial de la OMS sobre salud, medio ambiente y cambio climático, y se basa en los compromisos establecidos en la Agenda de Salud Sostenible para las Américas 2018-2030 y el Plan Estratégico de la OPS 2020-2025. La agenda se elaboró en consulta con el grupo técnico asesor y mediante un proceso de toma de decisiones basado en el consenso con los Estados Miembros durante el período 2019-2020. Con la finalidad de alcanzar el Objetivo de Desarrollo Sostenible 3, la agenda se centra en: mejorar el desempeño de los programas e instituciones de salud pública ambiental; fomentar sistemas de salud sostenibles y resilientes desde el punto de vista medioambiental; y promover ciudades y comunidades saludables y resilientes desde el punto de vista medioambiental. Su aplicación será específica para cada contexto y se basará en las necesidades y realidades de los diversos países. Beneficiará a los países y territorios al promover prácticas de buena gobernanza, fortalecer el liderazgo y la coordinación en el sector de la salud, fomentar la acción intersectorial, centrarse en la prevención primaria, y mejorar la evidencia disponible y la comunicación. Facilitará el acceso a los recursos humanos, técnicos y financieros necesarios para abordar los determinantes ambientales de la salud y garantizará que la Región se involucre plenamente en los procesos y acuerdos mundiales sobre salud, medioambiente y cambio climático.
more
The leishmaniases are a group of diseases caused by Leishmania spp., which occur in cutaneous, mucocutaneous and visceral forms. They are neglected tropical diseases (NTDs), which disproportionately affect marginalized populations who have limited access to health care. HIV co-infected patients with... Leishmania infection are highly infectious to sandflies, and an increase in the coinfection rate in an endemic area is likely to increase the effective infective reservoir.
more
Climate change and health vulnerability and adaptation assessment
In 2013 the World Health Organization (WHO) published the report Protecting health from climate change:
vulnerability and adaptation assessment. The aim was to provide basic and flexible guidance on conducting national or subnati...onal assessments of current and future vulnerability (the susceptibility of a population or region to harm) to the health risks of climate change, and of policies and programmes that could increase resilience, taking into account the multiple determinants of climate-sensitive health outcomes.
That guidance has been a very useful tool, applied to more than 50 countries and settings, and has helped countries to prepare their health contributions to United Nations Framework Convention on Climate Change national adaptation plans.
Since the launch of the guidance, WHO, technical partners such as Health Canada, and countries have learned much in terms of its applicability in different countries, at national and local levels.
At the same time, knowledge on climate change and health has increased.
WHO, the Pan American Health Organization and Health Canada have produced this updated version, which aims to better support countries in their assessments by proposing a simpler tool that incorporates all lessons learned.
more
New data from the WHO reveal that an estimated 2.2 billion cases of malaria and 12.7 million deaths have been averted since 2000, but the disease remains a serious global health threat, particularly in the WHO African Region. According to WHO’s latest World malaria report, there were an estimated ...263 million cases and 597 000 malaria deaths worldwide in 2023. This represents about 11 million more cases in 2023 compared to 2022, and nearly the same number of deaths. Approximately 95% of the deaths occurred in the WHO African Region, where many at risk still lack access to the services they need to prevent, detect and treat the disease.
more
This paper was commissioned by N´weti and Wemos as part
of the project “Equitable health financing for a strong health
system in Mozambique”. Its purpose is to contribute to the
debate of the Mozambican Ministry of Health’s draft Health
Sector Financing Strategy (HSFS) 2025 – 2034
One approach to development assistance for health, or health aid, emphasizes the ex ante selection of cost-effective health interventions, an approach that began with the World Development Report (1993) on Investing in Health and has since been adopted by the Effective Altruism community. But just h...ow much of health aid is cost-effective? In this paper, we examine projects in the Organisation for Economic Co-operation and Development (OECD) Creditor Reporting System, the standard dataset that measures and characterizes development assistance for health, for the
years 2019 to 2021, and count the number of projects that refer to interventions from a list of highly cost-effective interventions as defined by the Disease Control Priorities Project, third edition. This exploratory quantitative analysis indicates that 61% of projects used a key word/phrase of a costeffective intervention. There were 11.9 interventions mapped per project on average. There is little evidence that donors tailor the set of interventions to country income levels by cost-effectiveness.
Policymakers may benefit from reviewing the full portfolio of interventions covered by domestic and external resources.
more
En su condición de departamento técnico de la OMS para el paludismo, al Programa Mundial sobre Malaria le corresponde una importante función de liderazgo de la respuesta mundial. Por medio de sus acciones directas y su red, tiene la capacidad de conformar el ecosistema de la respuesta al paludism...o y lograr un impacto a nivel de los países. Teniendo esto en cuenta, el Programa Mundial sobre Malaria ha elaborado una estrategia operativa en la que se exponen sus prioridades para el periodo 2024-2030 y las cuatro palancas estratégicas para controlar y eliminar el paludismo que son parte esencial del mandato del Programa: normas y criterios, nuevos instrumentos e innovación, información estratégica para generar impacto, y liderazgo. La estrategia describe el modo en que el Programa Mundial sobre Malaria se transformará también por medio de una colaboración más eficaz con otros programas, con las oficinas regionales y en los países, y con los asociados, tomando como guía las enseñanzas extraídas del Decimotercer Programa General de Trabajo (13.º PGT) de la OMS y las prioridades del 14.º PGT.
more
En tant que département technique de l'OMS chargé du paludisme, le Programme mondial de lutte contre le paludisme a un rôle important à jouer dans la conduite de la riposte mondiale contre cette maladie. Grâce à ses actions directes et à son réseau, il peut façonner l'écosystème du paludi...sme et avoir un impact au niveau des pays. Dans cette optique, le Programme mondial de lutte contre le paludisme a élaboré une stratégie opérationnelle décrivant ses priorités pour la période 2024-2030 et les 4 leviers stratégiques pour contrôler et éliminer le paludisme qui relèvent de manière décisive du mandat du Programme : normes et critères, nouveaux outils et innovation, informations stratégiques axées sur les résultats et leadership. La stratégie décrit la façon dont le Programme mondial de lutte contre le paludisme se transformera également en la mise en place d’une collaboration plus efficace avec d’autres programmes, les bureaux régionaux et pays ainsi que les partenaires, en s’appuyant sur les enseignements tirés du treizième programme général de travail de l'OMS (GPW13) et des priorités du GPW14.
more
Frequent efforts to revise the official development assistance (ODA) accounting rules have raised important questions about the integrity and relevance of what currently “counts” as ODA spending. In this note, we outline a brief history of the evolution of the ODA accounting rules to date, highl...ighting how—and why—the ODA concept has changed since it emerged in 1969. Doing so provides a starting point for considering whether the current concept of ODA remains “fit for purpose” and whether, or how, the concept could reform to better meet current needs.
more
The guidelines are primarily intended for health-care professionals working in first- or second-level health-care facilities, including emergency, inpatient and outpatient services. They are also directed at policy-makers, health-care planners and programme managers, academic institutions, non-gover...nmental and civil society organizations to inform capacity-building, teaching and research agendas.
Web annex A provides the quantitative evidence reports, Web annex B summarizes the qualitative and economic evidence and Web annex C presents the Evidence-to-Decision frameworks.
more
The objectives of this guideline are the same as those of the 2011 edition, namely to provide evidence-based normative guidance on interventions to improve adolescent morbidity and mortality by reducing the chances of early pregnancy and its resulting poor health outcomes. The specific objectives of... the guideline were to: 1. identify effective interventions to prevent early pregnancy by influencing factors such as early marriage, coerced sex, unsafe abortion, access to contraceptives and access to maternal health services by adolescents; and 2. provide an analytical framework for policy-makers and programme managers to use when selecting evidence-based interventions to prevent early pregnancy and negative health outcomes when they occur that are most appropriate for the needs of their countries and context. The recommendations and best practice statements described in this document aim to enable evidence-based decision-making with respect to preventing early pregnancy and poor reproductive outcomes among adolescents in low- and middle-income country contexts.
more
The document outlines essential steps and provides guidance to countries on the adoption and deployment of c-IPTp so that it is integrated into the existing health system. It draws upon best practices and lessons learned from pilot implementation experiences in eight African countries and targets st...akeholders at the national level that are involved in the provision of maternal and child services, including national and local policymakers and implementers of malaria, maternal health, child health, reproductive health and community health programmes, and nongovernmental and other organizations.
more
Le guide décrit les étapes essentielles et donne des orientations aux pays pour l’adoption et le déploiement du c-TPIg de manière à l’intégrer dans le système de santé existant. Il s’appuie sur les meilleures pratiques et les enseignements tirés des expériences pilotes dans 8 pays af...ricains et vise toutes les acteurs impliqués dans la prestation des services pour la mère et l’enfant - responsables politiques nationaux et locaux et acteurs de mise en œuvre des programmes de lutte contre le paludisme, de la santé maternelle, de la santé de l’enfant, de la santé reproductive, des programmes de santé communautaires - ainsi que les organisations non gouvernementales et d’autres organismes. Les pays décidant d’introduire le c-TPIg sont invités à adapter ces orientations à leurs contextes nationaux et locaux.
more
O guia de campo apresenta os passos essenciais e dá orientações aos países sobre a adoção e utilização do c TPIg-c para o integrar no sistema de saúde existente. Baseia-se nas melhores práticas e nas lições aprendidas com as experiências de implementação piloto em oito países african...os, e destina-se às partes interessadas a nível nacional que estão envolvidas na prestação de serviços de saúde materna e infantil, incluindo os decisores políticos a nível nacional e local e os implementadores de programas de paludismo e saúde materna, infantil, reprodutiva e comunitária, assim como organizações não governamentais e outras.
more
WHO recommends artemisinin-based combination therapies for treating uncomplicated malaria, alongside studies to monitor treatment effectiveness. Given the threat of antimalarial resistance, including partial resistance in several African countries, molecular tools are vital for tracking resistance. ...In 2015, WHO launched the External Quality Assessment scheme for nucleic acid amplification testing to ensure reliable lab results. Coordinated by WHO and operated by the United Kingdom National External Quality Assessment Service for Parasitology, the scheme provides quality-controlled specimens and reports to help improve testing accuracy. Experts recently discussed expanding the scheme to include antimalarial resistance markers.
more
Clinical Pharmacology: Advances and Applications, 2025:17 29–47